CJC-1295

CJC-1295 API

CJC-1295he synthetic, tetrasubstituted peptide analogue ohormone hoʻokuʻu i ka ulu (GHRH), i hoʻolālā ʻia ehoʻoulu a mālama i ka mea huna o ka hormone ulu ulu (GH). ʻAʻole like me GHRH maoli, nona ka hapalua o ke ola pōkole, CJC-1295 hoʻokomo i kahiʻenehana hoʻohuihui lāʻau lāʻau (DAC)., e ʻae ana e hoʻopaʻa covalently i albumin i loko o ke kahe koko ae hoʻolōʻihi i kona hapalua ola ola a ʻoi aku ma mua o 8 mau lā. Hana kēia hana hou i ka CJC-1295 aanalogue GHRH lōʻihime ka mana nui ianti-kahiko, ulu hemahema, metabolic regulation, muscle-wasting disorders, a me ka laau hooulu hou.

Mechanism of Action

CJC-1295 hana ma kaGHRH loaʻaAia ma nā pūnaewele somatotropic i loko o ka pituitary gland anterior. ʻO kāna hana olaola e like me ka GHRH maoli, akā me ka hapalua o ke ola ma muli o ka hoʻololi DAC. Hiki i kēia hana hoʻomauhoʻokuʻu puʻupuʻu paʻa o GHa mahuahua ka hana ana omea ulu e like me ka insulin 1 (IGF-1).

Loaʻa nā mīkini koʻikoʻi:

• ʻO ka hoʻouluʻana i ka huna GH endogenous

• ʻO ke kiʻekiʻe lōʻihi o nā pae IGF-1, kākoʻo i nā hopena anabolic

• ʻAʻohe desensitization nuia i ʻole downregulation me ka hoʻohana mau ʻana

• Hoʻonui i ka lipolysis, ka synthesis protein, a me ka hoʻoulu hou ʻana o ka cellular

Ma ka hoʻoulu ʻana i nā ala GH a me IGF-1 o ke kino, pale ʻo CJC-1295 i ka nui o nā drawbacks e pili ana me ka exogenous GH therapy, e like me ka desensitization receptor a me nā hopohopo palekana.

Noiʻi Lapaʻau a me ka hiki ke hoʻomaʻamaʻa

1. ʻAʻole ʻo Growth Hormone Deficiency (GHD)

I nā hoʻokolohua lapaʻau mua, ua hōʻike ʻo CJC-1295:

• Hoʻonui mau i kaGHaIGF-1pae a hiki i6-10 lāma hope o hoʻokahi injection

• Hoemiiaka pinepine o ka injectionhoʻohālikelike ʻia me nā analogues GHRH i kēlā me kēia lā a i ʻole GH injections

• Hoʻomaikaʻi i ka mālama ʻana i ka maʻi a me ke kūpaʻa hormonal

2. Hoʻohui kino a me ka mālama ʻana i nā ʻiʻo

Ua hōʻike ʻia nā haʻawina holoholona a me nā kānaka i ka CJC-1295:

• Hoʻolahaloaʻa ka ʻiʻo wīwīahoemi i ka momona o ke kino, ʻoi aku ka momona visceral

• Hoʻonuika mālama ʻana i ka nitrogen a me ka synthesis proteini loko o ka ʻiʻo iwi

• Hiki ke kōkua i ka ho'ōla maisarcopeniaa me nā kūlana hoʻopau ʻiʻo

3. Nā mea hoʻohana kūʻē i ka ʻelemakule a me ke olakino

I ka emi ʻana o nā pae GH a me IGF-1 me ka makahiki, ua aʻo nui ʻia ʻo CJC-1295 ma ke ʻano hehana kūʻē i ka ʻelemakulei:

• Hoʻomaikaʻimaikaʻi moeahoʻoponopono circadian rhythm

• Hoʻonuiʻili elasticity, iwi iwi, ahana kino

• Kākoʻoikehu metabolismapale ʻana i ka luhi

4. Hoʻoponopono Metabolic

Hōʻike ʻo CJC-1295 i ka ʻōlelo hoʻohiki ma ke kamaʻilio ʻanapale ʻana i ka insulina me ka metabolic syndrome e:

• Hoʻomaikaʻika hoʻohana glucose

• Hoʻonuihoʻohāhā lipidakaʻiʻo adipose metabolism

• Kākoʻomālama kaumahai ka poʻe obese a i ʻole ma mua o ka maʻi diabetes

Hana ʻia API a me ka mana maikaʻi

At Pūʻulu Gentolex, ko makouCJC-1295 APIhana ʻia me ka hoʻohana ʻanaka hana peptide synthesis (SPPS)a hoʻomaʻemaʻe ʻia me ka hoʻohana ʻana i ka HPLC e hoʻokō i ka maʻemaʻe kiʻekiʻe a me ka paʻa ʻana o ka hui.

Nā ʻōlelo kikoʻī:

• Maʻemaʻe ≥ 99%(HPLC hōʻoia ʻia)

• ʻO nā mea hoʻoheheʻe koena haʻahaʻa a me nā metala kaumaha

• Endotoxin-noa, non-immunogenic synthesis ala

• Loaʻa manā nui maʻamau: milligram to kilo scale

Nā noi a me ka hiki i ka wā e hiki mai ana

Manaʻo ʻia ʻo CJC-1295 kekahi o nā mea hoʻohālikelike GHRH lōʻihi loa, me nā noi kūpono i:

• ʻO ka hoʻomaʻamaʻa hemahema GH makua

• Hoʻoponopono kino i ka momona a me ka ʻelemakule

• Hoʻoponopono hou mai ka nalo ʻana o ka ʻiʻo a i ʻole ka ʻeha

• Hoʻonui ka hana a me ka hoʻihoʻi hou ʻana i nā hoʻonohonoho lāʻau lapaʻau a haʻuki paha

• Kākoʻo kākoʻo i ka luhi mau loa, fibromyalgia, a me ka ʻole neuroendocrine

Ke ʻimi nei nā hoʻokolohua lapaʻau i kona hoʻohana ʻana ma ke ʻano he ʻokoʻaGH hui hou, ʻoi aku ka nui o ka poʻe e ʻimi neipalekana, ʻoi aku ka hoʻololi ʻana o ka hormone physiological.